Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design.

Autor:	McLaughlin JM; Pfizer Vaccines, Collegeville, Pennsylvania., Jiang Q; Pfizer Vaccines, Collegeville, Pennsylvania., Isturiz RE; Pfizer Vaccines, Collegeville, Pennsylvania., Sings HL; Pfizer Vaccines, Collegeville, Pennsylvania., Swerdlow DL; Pfizer Vaccines, Collegeville, Pennsylvania., Gessner BD; Pfizer Vaccines, Collegeville, Pennsylvania., Carrico RM; Department of Medicine, Division of Infectious Diseases, School of Medicine, University of Louisville, Kentucky., Peyrani P; Department of Medicine, Division of Infectious Diseases, School of Medicine, University of Louisville, Kentucky., Wiemken TL; Department of Epidemiology and Population Health, School of Public Health and Information Sciences, University of Louisville, Kentucky., Mattingly WA; Department of Medicine, Division of Infectious Diseases, School of Medicine, University of Louisville, Kentucky., Ramirez JA; Department of Medicine, Division of Infectious Diseases, School of Medicine, University of Louisville, Kentucky., Jodar L; Pfizer Vaccines, Collegeville, Pennsylvania.
Jazyk:	angličtina
Zdroj:	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2018 Oct 30; Vol. 67 (10), pp. 1498-1506.
DOI:	10.1093/cid/ciy312
Abstrakt:	Background: Following universal recommendation for use of 13-valent pneumococcal conjugate vaccine (PCV13) in US adults aged ≥65 years in September 2014, we conducted the first real-world evaluation of PCV13 vaccine effectiveness (VE) against hospitalized vaccine-type community-acquired pneumonia (CAP) in this population. Methods: Using a test-negative design, we identified cases and controls from a population-based surveillance study of adults in Louisville, Kentucky, who were hospitalized with CAP. We analyzed a subset of CAP patients enrolled 1 April 2015 through 30 April 2016 who were aged ≥65 years and consented to have their pneumococcal vaccination history confirmed by health insurance records. Cases were defined as hospitalized CAP patients with PCV13 serotypes identified via culture or serotype-specific urinary antigen detection assay. Remaining CAP patients served as test-negative controls. Results: Of 2034 CAP hospitalizations, we identified PCV13 serotypes in 68 (3.3%) participants (ie, cases), of whom 6 of 68 (8.8%) had a positive blood culture. Cases were less likely to be immunocompromised (29.4% vs 46.4%, P = .02) and overweight or obese (41.2% vs 58.6%, P = .01) compared to controls, but were otherwise similar. Cases were less likely to have received PCV13 than controls (3/68 [4.4%] vs 285/1966 [14.5%]; unadjusted VE, 72.8% [95% confidence interval, 12.8%-91.5%]). No confounding was observed during adjustment for patient characteristics, including immunocompromised status, body mass index, and history of influenza and pneumococcal polysaccharide vaccination (adjusted VE range, 71.1%-73.3%). Conclusions: Our study is the first to demonstrate real-world effectiveness of PCV13 against vaccine-type CAP in adults aged ≥65 years following introduction into a national immunization program.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu